Development and Validation of a Stability-Indicating RP-HPLC Method for the Simultaneous Determination of Sofosbuvir, Velpatasvir, and Voxilaprevir in Tablet Formulation

By Deepthi R & Gowri Sankar D

Abstract- Objective: The present study aimed to develop a stability-indicating reverse-phase high performance-liquid chromatography (RP-HPLC) method for the estimation of Sofosbuvir, Velpatasvir, and Voxilaprevir in tablet dosage form and validated in accordance with ICH guidelines.

Methods: The optimized conditions for the developed RP-HPLC method are Agilent C18 (250 mm×4.6mm, 5µ) column maintained at 30ºC with a mobile phase consisting of Buffer(0.1%OPA) and Acetonitrile taken in the ratio 55:45%v/v on isocratic mode at flow rate 1.0ml/min. The sample was detected at 220 nm.

Results: The retention time of Sofosbuvir, Velpatasvir, and Voxilaprevir was found to be 2.17, 2.731 and 3.55 min respectively. The developed method was validated for accuracy, precision, specificity, ruggedness, robustness and solution stability.

Keywords: stability-indicating, method development, validation, RP-HPLC, sofosbuvir.

GJMR-B Classification: NLMC Code: QV 55

Strictly as per the compliance and regulations of:
Development and Validation of a Stability-Indicating RP-HPLC Method for the Simultaneous Determination of Sofosbuvir, Velpatasvir, and Voxilaprevir in Tablet Formulation

Deepthi R & Gowri Sankar D

Abstract- Objective: The present study aimed to develop a stability-indicating reverse-phase high performance-liquid chromatography (RP-HPLC) method for the estimation of Sofosbuvir, Velpatasvir, and Voxilaprevir in tablet dosage form and validated in accordance with ICH guidelines.

Methods: The optimized conditions for the developed RP-HPLC method are Agilent C18 (250 mm×4.6mm, 5µ) column maintained at 30ºC with a mobile phase consisting of Buffer(0.1%OPA) and Acetonitrile taken in the ratio 55:45%v/v on isocratic mode at flow rate 1.0ml/min. The sample was detected at 220 nm.

Results: The retention time of Sofosbuvir, Velpatasvir, and Voxilaprevir was found to be 2.17, 2.731 and 3.55 min respectively. The developed method was validated for accuracy, precision, specificity, ruggedness, robustness and solution stability. The method obeyed Beer’s law in the concentration range of 10µg/ml-60µg/ml for Sofosbuvir, 2.5µg/ml-15µg/ml for Velpatasvir and 2.5µg/ml -15µg/ml for Voxilaprevir with a correlation coefficient of 0.999 for Sofosbuvir, Velpatasvir, and Voxilaprevir respectively.

Forced degradation studies were conducted by exposing the drug solution to various stress conditions such as acidic, basic, peroxide, neutral, photolytic and thermal conditions. The net degradation was found to be within the limits, indicating that the drug is stable in stressed conditions.

Conclusion: The developed method for the estimation of Sofosbuvir, Velpatasvir, and Voxilaprevir can be utilized for the routine analysis of the pharmaceutical dosage form.

Keywords: stability- indicating, method development, validation, RP-HPLC, sofosbuvir.

1. Introduction

Hepatitis C [1] is a liver infection which is caused by the Hepatitis C virus. The hepatitis C virus is a blood-borne virus and the most common modes of infection are through exposure to small quantities of infected blood. Globally, around 70 million people were suffering from Hepatitis C infection. Antiviral medicines like sofosbuvir, velpatasvir, and voxilaprevir, etc; can cure more than 95% of persons having Hepatitis C infection and reduce the causes of death.

Sofosbuvir [2] (Fig 1) is a nucleotide prodrug and a hepatitis C virus (HCV) NS5B polymerase inhibitor with potential HCV inhibiting activity. Used as an antiviral drug in the treatment of Hepatitis C virus. It is chemically (S)-Isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4dioxo3,4dihydropyrimidin1(2H)yl)4fluoro3hydroxy4methyltetrahydrofuran2yl)methoxy)(phenoxy)phenylamino) propanoate.

Velpatasvir [3] (Fig 2) is a NS5A inhibitor which is used together with sofosbuvir to treat chronic Hepatitis C infection. Used as an antiviral drug in the treatment of Hepatitis C virus. Chemically it is methyl {(2S)-1-[(2S,5S)-2-(9-{2-[2S,4S]-1-[(2R)-2-[(methoxy carbonyl) amino]-2-phenylacetyl}-4-(methoxy methyl) pyrrolidin-2-yl]-1H-imidazol-4-yl]-1,11-dihydro[2] benzo-pyra-no[4′,3′:6,7]naptho[1,2-d][imidazol-2-yl]-5-methyl-pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl} carbamate.
Voxilaprevir [4] (Fig 3) is a protease inhibitor and acts as a transporter of polypeptide. Used as an antiviral drug in the treatment of Hepatitis C virus. Chemically it is \((1R,18R,20R,24S,27S,28S)N\{(1R,2R)\)
\(2\text{[Difluoromethyl]}\}{1\{(1\text{methylcyclopropyl)sulfonyl\[carbamoyl\]cyclopropyl\]-28-ethyl-13,13-difluoro-7-methoxy-24-(2-methyl-2-propanyl)-22,25-dioxo-2,21diox4,11,23, 26-tetra aza penta cyclo nonacosa-3(12),4,6,8,10-pentaene-27-carboxamide.\}

**Figure 3: Structure of Voxilaprevir**

As per the literature survey [5 -11], it is learned that very few HPLC methods have been reported for the determination of Sofosbuvir, Velpatasvir, and Voxilaprevir individually and in combination by HPLC but there is no method for stability-indicating and simultaneous estimation of all the three drugs.

Therefore, there is a need to develop a rapid and reliable Stability-indicating HPLC method for the simultaneous determination of Sofosbuvir, Velpatasvir, and Voxilaprevir in bulk and pharmaceutical dosage form.

### II. Materials And Methods

**a) Reagents and chemicals**

Sofosbuvir, Velpatasvir and Voxilaprevir working standards were procured from spectrum pharma research solutions, Hyderabad, as a gift sample. The VOSEVI tablets were supplied by the Medindia Pharma network. All the chemicals used were of AR grade purchased from Merck, Mumbai. All the solvents used were of HPLC grade purchased from Sigma-Aldrich, Mumbai.

**b) Chromatographic conditions and Instruments**

WATERS HPLC 2695 SYSTEM equipped with quaternary pumps, Photo Diode Array detector, and an auto sampler integrated with Empower 2 software and Agilent C18 (250mm × 4.6mm, 5µ) column was used for the determination of Sofosbuvir, Velpatasvir, and Voxilaprevir. The optimized conditions included 0.1% Orthophosphoric acid (OPA) and acetonitrile (55:45%v/v) as mobile phase run on an isocratic mode at flow rate 1.0ml/min. The column was maintained at 300C and detection was done at 220nm. Other equipment used in the method was Ultrasonic bath sonicator (BVK Enterprises) and weighing balance (Denver).

c) Preparation of Diluent

A mixture of water and acetonitrile in the ratio of 50:50%v/v was used as diluents.

d) Preparation of Mobile phase

A mixture of 0.1% orthophosphoric acid and Acetonitrile in the ratio (55:45%v/v) was used as the mobile phase.

e) Preparation of Standard and Sample solutions

20mg, 5mg & 5mg of Sofosbuvir, Velpatasvir and Voxilaprevir working Standards were transferred to 50ml of volumetric flasks separately, 3/4th of diluents (as mentioned) was added to all the three flasks and subjected for sonication for 10 minutes. The final volume was made up with diluents to obtain a final concentration of 400µg/ml of Sofosbuvir, 100µg/ml of Velpatasvir, & 100µg/ml of Voxilaprevir respectively.

From the above stock solution, 1 ml was pipetted out into a 10ml volumetric flask and then the final volume was made with the same diluent. (40µg/ml of Sofosbuvir, 10µg/ml of Velpatasvir and 10µg/ml of Voxilaprevir respectively)

10 Tablets (Vosevi) were weighed accurately and the average weight was calculated. An amount equivalent of 1 tablet was collected into a 50ml volumetric flask; 15ml of diluents was mixed and sonicated for around 30 minutes. It was then subjected to making the volume with diluents.

Filtered the solution and diluted 1ml of the above solution to 10ml with diluents. (40µg/ml of Sofosbuvir & 10µg/ml of Velpatasvir & 10µg/ml of Voxilaprevir).

f) Method Validation

The developed method was validated in compliance with International Conference on Harmonization (ICH) guidelines [12, 13].

g) Specificity

The specificity of the method was determined by comparing the drug solution with the placebo solution and observed for the interference of placebo peak with drug peak.

h) Accuracy

The accuracy of the present method was determined by %recovery. The drug solution along with the sample was prepared in three concentration levels 50%, 100%, and 150%. Then the % recovery was calculated.

i) Precision

The precision of the method was estimated by injecting the six solutions of the standard into the HPLC system and the % relative standard deviation (%RSD) was calculated.
j) Linearity
The linearity of the method was developed by preparing series of dilutions ranging from 12.5µg/ml to 75µg/ml for Bictegravir, 50µg/ml-300µg/ml for Emtricitabine and 6.25µg/ml-37.5µg/ml for Tenofovir alafenamide respectively and injecting them into HPLC system.

k) Ruggedness
Ruggedness was determined by injecting the six solutions of the standard into HPLC for different days. The % RSD was calculated.

l) Robustness
Robustness of the method was determined by varying the optimized analytical conditions such as mobile phase composition by ±5%, flow rate by ±0.1ml/min and column temperature by ±5ºC.

m) LOD and LOQ
Calculation of limit of detection as well as Limit of quantification had been done by using standard Equations. LOD = 3.3×σ/S, LOQ =10×σ/S. Here σ denotes for the standard deviation of intercepts of regression lines, S denotes for slope.

n) Solution stability
Solution stability was estimated by analyzing the standard drug solution after storage for 24hrs under laboratory conditions.

o) Forced degradation studies
Forced degradation studies[14] were carried out for drug by exposing the drug solution to the various stress conditions such as acidic (2N Hydrochloric acid for 30min at 60ºC), basic (2N Sodium hydroxide for 30min at 60ºC), Oxidation (refluxing the drug solution with 20%H2O2), neutral (refluxing the drug in water for 6h at 60ºC), photolytic (exposing the drug solution to UV light by keeping the solution in UV chamber for 7 days or 200-watt hrs/m2 in photostability chamber), thermal (drug solution was placed in oven at 105ºC for 6hrs)

III. Results

![Image](image_url)

**Figure 4:** Optimized chromatogram of Sofosbuvir, Velpatasvir, and Voxilaprevir

**Table 1:** System suitability and validation parameter results

| Parameter                  | Result  |
|----------------------------|---------|
| USP Plate count            | 4088    |
| USP Tailing factor         | 1.0     |
| USP Resolution             | 4.5     |
| Precision (%RSD)           | 0.9     |
| Accuracy                   | 98.50-101.50 |
| Specificity                | Specific, No interference |
| Linearity range (µg/ml)    | 10-60   |
| Correlation coefficient, r²| 0.999   |
| LOD (µg/ml)                | 0.11    |
| LOQ (µg/ml)                | 0.34    |
| Ruggedness (%RSD)          | 0.9     |
| Day1                       | 0.9     |
| Day2                       | 0.9     |
| Robustness (%RSD)          | 1.2     |
| Flow rate –                | 1.2     |
Flow rate + 3.4 3.7 3.7
Column temperature – 2.8 2.7 2.9
Column temperature + 2.2 2.4 2.2
Mobile phase – 3.8 3.4 3.2
Mobile phase + 2.4 2.7 2.4
Solution stability (%RSD)
(0 hrs) 1.0 0.6 1.0
(24 hrs) 0.9 1.0 0.6

Table 2: Forced degradation studies result

| Stress condition | Sofosbuvir | Velpatasvir | Voxilaprevir |
|------------------|-----------|-------------|--------------|
| %Assay           | %D        | %Assay      | %D           | %Assay       | %D           |
| Acid             | 94.23 5.77| 94.04 5.96  | 94.14 5.86   |
| Base             | 95.35 4.65| 95.10 4.9   | 94.49 5.51   |
| Neutral          | 99.37 0.63| 99.51 0.49  | 99.67 0.33   |
| Peroxide         | 95.95 4.05| 95.58 4.42  | 96.61 3.39   |
| Photolytic       | 97.73 2.27| 97.58 2.42  | 99.08 0.92   |
| Thermal          | 98.22 1.75| 96.43 3.57  | 98.71 1.29   |

%D- Percentage Degradation

**Figure 5:** Blank chromatogram

**Figure 6:** Standard chromatogram
Figure 7: Sample chromatogram

Figure 8: Placebo chromatogram

Figure 9: Linearity plot of Sofosbuvir

Figure 10: Linearity plot of Velpatasvir
Development and Validation of a Stability-Indicating RP-HPLC Method for the Simultaneous Determination of Sofosbuvir, Velpatasvir, and Voxilaprevir in Tablet Formulation

Figure 11: Linearity plot of Voxilaprevir

\[ y = 25052x + 1805. \]
\[ R^2 = 0.999 \]

Figure 12: HPLC Chromatogram of Acid Degraded sample

Figure 13: HPLC Chromatogram of Alkali Degraded sample

Figure 14: HPLC Chromatogram of Peroxide Degraded sample
For the development of a new method for the simultaneous estimation of Sofosbuvir, Velpatasvir, and Voxilaprevir in bulk and pharmaceutical dosage form initially many mobile phases and many columns were tried to elute the drug peak with less tailing factor, more plate count and more resolution.

Waters HPLC Agilent C18 (250mm × 4.6mm, 5µ) column and Buffer: Acetonitrile (55:45%v/v) as mobile phase were selected based on peak parameters. The detection wavelength was found to be 220nm.

Prepared standard solution, sample solution, and blank solution were injected into the HPLC system and system suitability parameters were noted as summarized in Table 1 along with chromatograms as shown in fig. 4, 5, 6 and 7 respectively.

The developed method was found to obey Beer’s law in the concentration range of 10-60 µg/ml for Sofosbuvir, 2.5-15 µg/ml for velpatasvir and 2.5-15 µg/ml for Voxilaprevir with a correlation coefficient of 0.999 each respectively. A linear graph was plotted between concentration and peak area as shown in fig.
9.10 and 11 respectively and results are summarized in Table 1.

The method was found to be accurate as the % recovery was 98.50%-101.50% for all the three drugs and was within the limits. The %RSD was found to be less than 1 for all the three drugs indicates that the method was precise. The method was found to be specific, as there is no interference of retention time of placebo peak with that of drug peak. The placebo chromatogram was shown as fig. 8.

Forced degradation studies results indicate that the drug was found to be stable in various stress conditions as net degradation was found to be within the limits. The chromatograms were shown in fig. 12-17 and results were summarized in Table 2.

V. Conclusion

A specific, precise, stability-indicating method was developed for the determination of Sofosbuvir, Velpatasvir, and Voxilaprevir in pure and tablet dosage form using RP-HPLC. The method was validated by using various validation parameters and the method was found to be linear, precise, accurate, specific and robust. From the degradation, studies conducted it is concluded that Sofosbuvir, Velpatasvir, and Voxilaprevir were stable at high concentrations of Acid, Base, Peroxide, Thermal, UV and Water stress study conditions. The run time was 5min which enables rapid quantitation of many samples in routine and quality control analysis of tablet formulations.

Acknowledgment

The authors are thankful to the pharma research solutions, Hyderabad for providing the Sofosbuvir, Velpatasvir, and Voxilaprevir as the gift samples and also for providing required facilities to carry out this research work.

Conflict of Interests

The authors claim that they have no conflict of interest. It has not meant to publish elsewhere. Moreover, it has not meant simultaneously presented for publication elsewhere.

References Références Referencias

1. https://www.who.int/news-room/fact-sheets/detail/hepatitisC
2. http://www.wikipedia.com/sofosbuvir
3. http://www.wikipedia.com/velpatasvir
4. http://www.wikipedia.com/voxilaprevir
5. Sandhya Rani J and Devanna N. Development and validation of RP-HPLC method for the simultaneous estimation of Sofosbuvir, velpatasvir, and voxilaprevir in bulk and tablet dosage forms. Rasayan chem. Journal, 2018; 11(I) 2:452 – 459.
6. Sandhya Rani J, Devanna N. New RP-HPLC method development and validation for simultaneous estimation of sofosbuvir and velpatasvir in a pharmaceutical dosage form. International Journal of Engineering Technology Science and Research, 2017; 4,(11):145-152.
7. Geetha Susmitha A and Rajitha G. Development and validation of stability indicating UPLC method for simultaneous estimation of sofosbuvir and velpatasvir in a tablet dosage form. International journal of pharmaceutical sciences and research, 2018; 9(11): 4764-4769.
8. Lakshmana Rao A and Pallavi A. Method Development and Validation of Stability Indicating RP-HPLC Method for Simultaneous Estimation of Sofosbuvir and Velpatasvir in Tablet Dosage Form. Pharmaceutical Sciences & Analytical Research Journal, 2019; 2(1):1-8.
9. Balaswami, B; Ramana, P Venkata; Rao, B Subba; Sanjeeva, P. A New Simple Stability-Indicating RP-HPLC- PDA Method for Simultaneous Estimation of Triplicate Mixture of Sofosbuvir, Velpatasvir, and Voxilaprevir in Tablet Dosage Form. Research Journal of Pharmacy and Technology, 2018; 11(9):4147-4156.
10. Memthoibi Devi L, Dr.Rama Mohan Reddy T, Dr.Abbulu K. Simultaneous determination and validation of third generation antiviral drugs by RP-HPLC method. International journal of pharmacy and analytical research, 2010; 8(1):1-8.
11. Lalitha KV, Raveendra Reddy J, and N Devanna N. Stability indicating RP-HPLC method development and validation for estimation of Sofosbuvir in a pharmaceutical dosage form. The Pharma Innovation Journal, 2018; 7(5):656-662.
12. ICH: Q2 [R1], Validation of analytical procedures: text and methodology; 2005.
13. ICH: Q2B. Harmonized Tripartite Guideline, Validation of Analytical Procedure: Methodology, IFPMA, in Proceedings of the International Conference on Harmonization, Geneva; 1996.
14. Ngwa G. Forced degradation studies as an integral part of HPLC stability indicating method development. Drug delivery Technol 2010; 10:56-59.